2023 World Conference on Lung Cancer (Posters)-P2.05. Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials

P2.05. Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials - PDF(Abstract)

Back to course

Pdf Summary

This study presented at the 2023 World Conference on Lung Cancer analyzed the impact of EGFR co-mutations on the efficacy of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients. The researchers used data from the OAK and POPLAR trials, which included advanced NSCLC patients treated with atezolizumab or docetaxel. Out of the EGFR-mutated patients treated with atezolizumab, 56 were enrolled in the study. The top 20 genes co-mutated with EGFR were identified, with TP53 and LRP1B ranking as the top two. <br /><br />The results showed that distinct EGFR co-mutation patterns had an impact on atezolizumab efficacy. Patients with EGFR&LRP1B co-mutations exhibited a higher objective response rate (ORR) and significantly improved overall survival (OS) and progression-free survival (PFS) compared to patients with EGFR single mutation (SM). Similarly, patients with EGFR&FAT3 co-mutations showed increased ORR and prolonged PFS compared to EGFR SM patients. Both EGFR&LRP1B and EGFR&FAT3 co-mutated patients had higher blood tumor mutational burden (bTMB) levels than EGFR SM patients, while PD-L1 expression levels were similar among the groups.<br /><br />The study suggests that EGFR co-mutation patterns have a substantial impact on the efficacy of ICIs. Patients with co-mutations of EGFR and LRP1B or FAT3 significantly benefited more from ICIs. This finding highlights the importance of considering co-mutations when determining the appropriate treatment approach for EGFR-mutated NSCLC patients.

Asset Subtitle

Wengang Zhang

Meta Tag

Speaker Wengang Zhang

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

EGFR co-mutations

immune checkpoint inhibitors

NSCLC patients

OAK trial

POPLAR trial

atezolizumab

TP53

LRP1B

FAT3

ICIs